Table 1.
Baseline characteristics of the development and validation cohorts.
| Overall (n=501) | Development cohort (n=351) | Validation cohort (n=150) | P-value | |
|---|---|---|---|---|
| Sex, No. (%) | 0.44 | |||
| Male | 262 (52.3) | 188 (53.6) | 74 (49.3) | |
| Female | 239 (47.7) | 163 (46.4) | 76 (50.7) | |
| Onset age, mean (SD), y | 44.6 (19.9) | 44.7 (19.5) | 44.3 (20.8) | 0.82 |
| Autoimmune comorbidities, No. (%) a | 0.22 b | |||
| No | 488 (97.4) | 344 (98.0) | 144 (96.0) | |
| Yes | 13 (2.6) | 7 (2.0) | 6 (4.0) | |
| Onset symptoms, No. (%) | 0.99 | |||
| Ptosis | 310 (61.9) | 217 (61.8) | 93 (62.0) | |
| Diplopia/diplopia and ptosis | 191 (38.1) | 134 (38.2) | 57 (38.0) | |
| RNS findings, No. (%) | 0.24 | |||
| Normal | 252 (50.3) | 170 (48.4) | 82 (54.7) | |
| Abnormal | 249 (49.7) | 181 (51.6) | 68 (45.3) | |
| AChR-Ab, No. (%) | 0.51 | |||
| Seronegative | 132 (26.3) | 89 (25.4) | 43 (28.7) | |
| Seropositive | 369 (73.7) | 262 (74.6) | 107 (71.3) | |
| Thymic status, No. (%) | 0.93 | |||
| Normal | 322 (64.3) | 226 (64.4) | 96 (64.0) | |
| Thymic hyperplasia | 100 (20.0) | 71 (20.2) | 29 (19.2) | |
| Thymoma | 79 (15.8) | 54 (15.4) | 25 (16.7) | |
| Neostigmine test, No. (%) | 0.99 b | |||
| Negative | 18 (3.8) | 13 (3.9) | 5 (3.5) | |
| Positive | 460 (96.2) | 323 (96.1) | 137 (96.5) | |
| Follow-up time, median (IQR), m | 15.0 [7.0,48.0] | 17.0 [7.0,48.0] | 12.5 [7.3,36.0] | 0.60 c |
| Generalization, No. (%) | 118 (23.6) | 83 (23.6) | 35 (23.3) | 0.99 |
SD, standard deviation; IQR, interquartile range; RNS, repetitive nerve stimulation; AChR-Ab, acetylcholine receptor antibody; No., number.
a
Autoimmune comorbidities included systemic lupus erythematosus, multiple sclerosis, rheumatoid arthritis, Hashimoto’s thyroiditis, and optic neuromyelitis spectrum disease.
b
Fisher exact test.
c
Mann−Whitney U test.